Medicare gets a one-year break on drug plan premiums—at federal expense
H.R. 10185 — Part D Premium Protection Act of 2026 · Filed by Gus Bilirakis (R-FL) · Introduced Aug 31, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the federal government to calculate a temporary discount on Medicare Part D prescription drug plan premiums for 2027, based on average premium reductions observed during a 2024–2026 demonstration project. The discount is applied directly to enrollees' premiums, with the government reimbursing insurance plans for the foregone revenue. Enrollees benefit through lower out-of-pocket costs; the government bears the cost.
Why we flagged it
The bill's operative mechanism is a direct, time-limited federal subsidy to reduce prescription drug plan premiums for Medicare enrollees. It is a targeted benefit program, not a regulatory change or industry carve-out.
What the text implies
- The credit is pegged to a specific demonstration project's results (July 29, 2024 announcement), making the benefit dependent on how that demonstration was designed and which plans participated—potential for variation in actual savings across regions or plan types.
- The credit is temporary (2027 only) and does not establish a permanent entitlement, creating uncertainty for beneficiaries about whether the discount will continue in 2028 and beyond.
The full analysis lists 4 implications of this text.
Who stands to gain
Medicare Part D enrollees (direct premium reduction); Prescription drug plan sponsors (full reimbursement of foregone premiums)